Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMMUNITY HEALTH SYSTEMS INCCYH · Entity 5628 | CEO | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMMUNITY HEALTH SYSTEMS INC
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 895,545 |
Ending reported balance
After 2026-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-01 · Exercise / conversion · Acquired 156,240 · Balance 792,441 F1: The vesting of these 180,000 performance-based restricted shares was based on the Issuer's attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2023-2025 Performance Period, the award vested on 3/1/2026 at 86.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2023 (156,240), and the remaining 13.2% of the target number has been forfeited (23,760). Row 2 · 2026-03-01 · Grant · Acquired 200,000 · Balance 992,441 F2: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Row 3 · 2026-03-01 · Tax withholding · Disposed 96,896 · Balance 895,545 |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,760 |
Reported balance
After 2026-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-01 · Exercise / conversion · Disposed 156,240 · Balance 23,760 F1: The vesting of these 180,000 performance-based restricted shares was based on the Issuer's attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2023-2025 Performance Period, the award vested on 3/1/2026 at 86.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2023 (156,240), and the remaining 13.2% of the target number has been forfeited (23,760). |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-01 · Disposition to issuer · Disposed 23,760 · Balance 0 F1: The vesting of these 180,000 performance-based restricted shares was based on the Issuer's attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2023-2025 Performance Period, the award vested on 3/1/2026 at 86.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2023 (156,240), and the remaining 13.2% of the target number has been forfeited (23,760). |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 400,000 |
Reported balance
After 2026-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-01 · Grant · Acquired 400,000 · Balance 400,000 F3: The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 40% to a Cumulative Same-Store Adjusted EBITDA Growth target; 40% to a Cumulative Same-Store Net Revenue Growth target; and 20% to a Total Shareholder Return ("TSR") Percentile Rank target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 180,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 180,000 F5: The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2024 and 12/31/2026 (the "2024-2026 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2024-2026 Performance Period. |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 180,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 180,000 F6: The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2025 and 12/31/2027 (the "2025-2027 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2025-2027 Performance Period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 · Expires 2036-02-29 | Direct | 200,000 |
Reported balance
After 2026-03-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-01 · Grant · Acquired 200,000 · Balance 200,000 F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2029-02-28 | Direct | 18,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 18,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.93 · Expires 2030-02-28 | Direct | 47,500 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 47,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.81 · Expires 2031-02-28 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 75,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18 · Expires 2032-02-29 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 75,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2033-02-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 90,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2034-02-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 90,000 F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2035-02-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2026-03-01 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 90,000 F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The vesting of these 180,000 performance-based restricted shares was based on the Issuer's attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2023-2025 Performance Period, the award vested on 3/1/2026 at 86.8% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2023 (156,240), and the remaining 13.2% of the target number has been forfeited (23,760).
F2: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
F3: The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 40% to a Cumulative Same-Store Adjusted EBITDA Growth target; 40% to a Cumulative Same-Store Net Revenue Growth target; and 20% to a Total Shareholder Return ("TSR") Percentile Rank target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period.
F4: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
F5: The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2024 and 12/31/2026 (the "2024-2026 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2024-2026 Performance Period.
F6: The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2025 and 12/31/2027 (the "2025-2027 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2025-2027 Performance Period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2018 Filed Jun 1, 2018 21:24 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | Tax withholdingCommon Stock | 2,624 | $3.97 | $10,417.28 |
DisclosureSEC source: 0001209191-18-034776 · doc4.xml · nonDerivative · entry 1 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,463 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 21:28 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantPerformance Based Restricted · Derivative | 18,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015658 · doc4.xml · derivative · entry 3 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-02-28 F2 · derivative.exercise_date: The vesting of 50% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Same-Store Adjusted EBITDA Growth between January 1, 2018 and December 31, 2020 (the "2018-2020 Performance Period"). The vesting of the remaining 50% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Same-Store Adjusted EBITDA Margin Improvement for the 2018-2020 Performance Period. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the target number of performance-based restricted shares subject to the attainment of the Cumulative Same-Store Adjusted EBITDA Growth and Cumulative Same-Store Adjusted EBITDA Margin Improvement criteria, as applicable, will ultimately vest on the third anniversary of the date of grant, with the vesting percentage to be determined based upon achievement with respect to the Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 21:28 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | Tax withholdingCommon Stock | 8,200 | $4.58 | $37,556.00 |
DisclosureSEC source: 0001209191-18-015658 · doc4.xml · nonDerivative · entry 2 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,087 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 21:28 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015658 · doc4.xml · nonDerivative · entry 1 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,287 F1 · shares: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:13 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037201 · doc4.xml · nonDerivative · entry 1 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,287 F1 · shares: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:14 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantPerformance Based Restricted · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016539 · doc4.xml · derivative · entry 3 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-02-28 F2 · derivative.exercise_date: The vesting of 80% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Same-Store Adjusted EBITDA Growth between January 1, 2017 and December 31, 2019 (the "Performance Period"). The vesting of the remaining 20% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Adjusted EPS for the Performance Period. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the target number of performance-based restricted shares subject to the attainment of the Cumulative Same-Store Adjusted EBITDA Growth and Cumulative Adjusted EPS criteria, as applicable, will ultimately vest on the third anniversary of the date of grant, with the vesting percentage to be determined based upon achievement with respect to the applicable criteria during the Performance Period. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:14 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | Tax withholdingCommon Stock | 12,586 | $9.19 | $115,665.34 |
DisclosureSEC source: 0001209191-17-016539 · doc4.xml · nonDerivative · entry 2 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,287 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:14 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016539 · doc4.xml · nonDerivative · entry 1 HAMMONS KEVIN J · CIK 0001542264 · Senior VP and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,873 F1 · shares: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.